Antibodies, methods and kits for diagnosing and treating melanoma

摘要

The present invention relates to a method of identifying if a subject is suitable for TCRL-based epitope directed therapy, comprising determining a level of epitope presentation on at least one cell of the subject using an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a peptide fragment of said antigen, wherein the antibody does not bind said MHC-I in the absence of said complexed peptide fragment of said antigen, and wherein the antibody does not bind said peptide fragment of said antigen in an absence of said MHC, wherein a level value higher than a predetermined threshold is indicative of an individual being suitable for TCRL-based epitope directed therapy. The present invention further relates to a method of identifying if a subject is suitable for CTL-based epitope directed therapy, comprising determining a level of epitope presentation on at least one cell of the subject using an antibody comprising an antigen recognition domain capable of binding to an MHC-I molecule being complexed with a peptide fragment of said antigen, wherein the antibody does not bind said MHC-I in the absence of said complexed peptide fragment of said antigen, and wherein the antibody does not bind said peptide fragment of said antigen in an absence of said MHC, wherein a level value lower than a predetermined threshold is indicative of an individual being suitable for CTL-based epitope directed therapy.